Form 4: Enliven Therapeutics' Chief Scientific Officer Exercises Options and Sells Shares

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, exercised stock options and sold shares on April 29, 2024, under a pre-arranged trading plan.

Summary

• On April 29, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, exercised stock options to acquire 12,000 shares of common stock at a price of $1.12 per share.
• Simultaneously, Lyssikatos sold 10,987 shares at a weighted average price of $17.8634 and 1,013 shares at a weighted average price of $18.4823.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Lyssikatos directly owns 0 shares and indirectly owns 1,117,035 shares through The Lyssikatos Revocable Trust 12/15/2011.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions were pre-planned under a Rule 10b5-1 trading plan, so they don't necessarily reflect the officer's current outlook on the company. Option exercises are generally positive, but the subsequent sale of shares tempers the overall sentiment.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. A pre-planned sale under Rule 10b5-1, however, is less indicative of current sentiment than discretionary trades.

Key Dates